Low power view showing marked hypercellularity with a
broad-spectrum of myeloid and erythroid cell types and marked
myeloid hyperplasia.
Review Date: 02/28/2011
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of
General Medicine, Department of Medicine, University of Washington
School of Medicine; Yi-Bin Chen, MD, Leukemia/Bone Marrow
Transplant Program, Massachusetts General Hospital. Also reviewed
by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org)
